Premium
CGRP and its receptors
Author(s) -
Hay Debbie L.,
Walker Christopher S.
Publication year - 2017
Publication title -
headache: the journal of head and face pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 119
eISSN - 1526-4610
pISSN - 0017-8748
DOI - 10.1111/head.13064
Subject(s) - calcitonin gene related peptide , receptor , amylin , calcitonin receptor , calcitonin , pharmacology , neuroscience , medicine , endocrinology , biology , neuropeptide , islet , insulin
The calcitonin gene‐related peptide (CGRP) neuropeptide system is an important but still evolving target for migraine. A fundamental consideration for all of the current drugs in clinical trials and for ongoing development in this area is the identity, expression pattern, and function of CGRP receptors because this knowledge informs safety and efficacy considerations. In recent years, only the calcitonin receptor‐like receptor/receptor activity‐modifying protein 1 (RAMP1) complex, known as the CGRP receptor, has generally been considered relevant. However, CGRP is capable of activating multiple receptors and could have more than one endogenous receptor. The recent identification of the CGRP‐responsive calcitonin receptor/RAMP1 complex (AMY 1 receptor – amylin subtype 1 receptor) in the trigeminovascular system warrants a deeper consideration of the molecular identity of CGRP receptor(s) involved in the pathophysiology, and thus potential treatment of migraine. This perspective considers some of the issues and implications.